Exozymes (Invizyne)
Americas
Monrovia
,
United States
Established
FOUNDED
2019
HEADCOUNT
21-100
FUNDING
Public
Keywords:
enzymes, cell_free, AI/ML, directed_evolution, biocatalysis, nutraceuticals, SAF, therapeutics
BUSINESS
ExoZymes (formerly Invizyne Technologies, Nasdaq: EXOZ) is a Los Angeles-area cell-free biomanufacturing company founded in 2019, publicly traded on Nasdaq. Develops cell-free biomanufacturing platforms using AI-engineered enzymes and synthetic pathways for production of pharmaceuticals, chemicals, and cannabinoids. The company originated from over a decade of research at UCLA (James Bowie lab) and has received approximately $14M in US government grants from NIH, DOE, and DOD. The company operates a capital-light licensing/partnership model and has demonstrated pilot-scale production of N-trans-Caffeoyltyramine (NCT), a nutraceutical/pharmaceutical candidate
BIOTECH INVOLVEMENT
Core: cell-free synthetic biology and enzymatic cascade systems for scalable biomanufacturing. eXoZymes engineers isolated enzymes using AI and directed evolution to function outside living cells in bioreactor cascade reactions, explicitly bypassing whole-cell fermentation. The platform uses "bioclick" group transfer reactions and cell-free cascade biotransformations to convert sugar/biomass feedstocks into target small molecules including nutraceuticals, pharmaceutical intermediates, cannabinoid analogs, and isobutanol for sustainable aviation fuel.
TECHNOLOGY PLATFORM
AI enzyme engineering; cell-free biocatalysis
PRIMARY PRODUCTS
Custom cell-free production of high-value molecules and APIs